Imidazo[1,2-α]pyridines.: Part 2:: SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors

被引：113

作者：

Byth, KF ^{[1
]}

Culshaw, JD ^{[1
]}

Green, S ^{[1
]}

Oakes, SE ^{[1
]}

Thomas, AP ^{[1
]}

机构：

[1] AstraZeneca, Macclesfield SK10 4TG, Cheshire, England

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2004年 / 14卷 / 09期

关键词：

CDK2; inhibitor;

D O I：

10.1016/j.bmcl.2004.02.015

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Exploration of SAR and optimisation of the imidazo[1,2-a]pyridine CDK inhibitors has lead to the discovery of novel, potent and selective inhibitors of the cyclin-dependent kinase CDK2. Understanding of SAR has identified positions Of Substitution, which allow modification of physical properties and offer the potential for in vivo optimisation. (C) 2004 Elsevier Ltd. All rights reserved.

引用

页码：2245 / 2248

页数：4

共 26 条

[21] Anticancer drug targets: cell cycle and checkpoint control [J].